Latest news
25 items- SECShineco Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events8-K - SHINECO, INC. (0001300734) (Filer)
- SECSEC Form NT 10-K filed by Shineco Inc.NT 10-K - SHINECO, INC. (0001300734) (Filer)
- PRShineco (SISI) Ignites Growth: $8.7M Tech Deal & Major Singapore Alliance Unleash Dual EnginesBEIJING, Sept. 12, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ:SISI) ("Shineco" or the "Company"), a developer and commercializer of induced pluripotent stem cell (iPSC) technology platforms, today announced two major strategic advances. Its subsidiary, Xi'an Dong'ao Health Management Co., Ltd. ("Dong'ao Health"), has signed a technology services contract valued at US$8.7 million with Xinke Future Biotechnology (Bazhou) Co., Ltd. for the research and development of "microalgae-derived extracellular vesicles" technology. Separately, a delegation from Singapore's leading biotechnology company, BICC, completed a productive site visit to Dong'ao Health on September 10. The parties reached a broad
- PRShineco Achieves Mass Production of High-Purity Physical Phospholipids, Breaking Foreign Monopoly and Unlocking Innovation Across IndustriesBEIJING, Sept. 10, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ:SISI) ("Shineco" or the "Company"), a leading developer of induced pluripotent stem cell (iPSC) technology platforms, today announced that its subsidiary, Fuzhou Meidashan Biotechnology Co., Ltd., has successfully achieved large-scale production of high-purity, highly active free-form soybean phospholipids. This breakthrough was made possible through its proprietary APCC-UF pure physical extraction technology, overcoming a persistent global technical challenge in the field. Testing by multiple authoritative institutions confirms that the product's key metrics meet internationally leading standards, providing robust technical suppor
- PRShineco (NASDAQ: SISI) & BICC: From "Tech On-Chain" to "Global Redeemability"--RWA Ecosystem Takes Off for Long-Term GrowthBEIJING, Aug. 27, 2025 /PRNewswire/ -- Shineco Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, has entered into a strategic cooperation agreement with Singapore-based BICC Pte Ltd to jointly promote the implementation and redemption of "on-chain cell assets" across multiple institutions and scenarios. This collaboration marks a new phase of "cross-enterprise redeemability" for cell assets on the blockchain, advancing the RWA ecosystem from "technical on-chain integration" to "real-world application. This partnership builds on Shineco's prior initiatives: establishing a Cell Digital Division,signing an agree
- PRShineco Unveils World's First On-Chain Cell Asset Tokenization Platform; Strategic Acquisition Expands Global Blockchain-Biotech NetworkBEIJING, Aug. 20, 2025 /PRNewswire/ -- Shineco Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a leading innovator in induced pluripotent stem cell (iPSC) technology, today announced the execution of a "Cellular Asset On-Chaining and Marketing Ecosystem Cooperation Agreement" with blockchain infrastructure provider Plus Me Limited. This partnership enables blockchain-based tokenization of biological cellular assets, facilitating seamless global transfers and auditable standardized custody, creating a novel 'Asset On-Chaining + Application Scenarios' model in cell therapy. The collaboration will redefine the global biological cell industry's commercial architecture. Under the agreeme
- PRShineco Establishes Biological Cell Digital Division to Integrate Biological Cell Assets and Blockchain TechnologyBEIJING, Aug. 13, 2025 /PRNewswire/ -- Shineco Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, today announced the establishment of a Biological Cell Digital Business Division (the "Division"), and the appointment of Mr. Lin Hongguang as General Manager, to advance the integration of its biological cell assets and blockchain technology. Through a new architecture of blockchain-based cell assets, Shineco aims to build a vertical ecosystem within the biological cell sector, accelerate the global distribution of biological cell products and boost global sales. The Division is expected to use blockchain technol
- PRShineco, Inc. to Effect 50:1 Reverse Stock SplitMeasure taken to Comply with Nasdaq Rule 5550(a)(2) Regarding Minimum Bid Price BEIJING, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. (NASDAQ:SISI) ("Shineco" or the "Company"), a provider of innovative diagnostic medical products and related medical devices, today announced that the Company's Board of Directors has approved a 50:1 reverse stock split of the Company's issued and outstanding common stock, par value $0.001 per share (the "Common Stock") to be effective 12:01 a.m., Eastern Time, on August 11, 2025. The Company's Common Stock will continue to trade on the Nasdaq Capital Market LLC under the symbol "SISI" following the reverse stock split, with a new CUSIP number of 8245676
- SECShineco Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events8-K - SHINECO, INC. (0001300734) (Filer)
- SECSEC Form DEF 14C filed by Shineco Inc.DEF 14C - SHINECO, INC. (0001300734) (Filer)
- SECShineco Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - SHINECO, INC. (0001300734) (Filer)
- SECSEC Form PRE 14C filed by Shineco Inc.PRE 14C - SHINECO, INC. (0001300734) (Filer)
- SECAmendment: Shineco Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K/A - SHINECO, INC. (0001300734) (Filer)
- SECShineco Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - SHINECO, INC. (0001300734) (Filer)
- SECShineco Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - SHINECO, INC. (0001300734) (Filer)
- SECShineco Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - SHINECO, INC. (0001300734) (Filer)
- PRManagement Confidence: Shineco Executives Launch up to $2M Open-Market Stock Purchase ProgramBEIJING, June 11, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a provider of innovative diagnostic medical products and related medical devices, today announced that Ms. Jennifer Zhan, the Company's chief executive officer, and Mr. Sam Wang, the Company's chief financial officer, will jointly initiate a stock purchase program (the "Stock Purchase Program") to purchase up to $2,000,000 of the Company's common stock, par value $0.001 per share (the "Common Stock") at a price of up to $1.50 per share, reflecting their strong beliefs that the Common Stock is undervalued. Under the Stock Purchase Program, purchases of the Common Stock will be made i
- SECShineco Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - SHINECO, INC. (0001300734) (Filer)
- SECSEC Form 10-Q filed by Shineco Inc.10-Q - SHINECO, INC. (0001300734) (Filer)
- SECAmendment: Shineco Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K/A - SHINECO, INC. (0001300734) (Filer)
- SECShineco Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - SHINECO, INC. (0001300734) (Filer)
- PRShineco's Subsidiary InfiniClone Partners with Total World Marketing for Entry into the Southeast Asian Healthcare MarketBEIJING, May 13, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a provider of innovative diagnostic medical products and related medical devices, today announced that InfiniClone Limited ("InfiniClone"), Shineco's majority-owned subsidiary in which the Company acquired a 51% equity interest on April 25, 2025, has officially launched its Southeast Asian market expansion strategy as it has reached a strategic distribution agreement with Total World Marketing (Thailand) ("TWM"), pursuant to which TWM will be responsible for the promotion and sale of InfiniClone's molecular detection kits and InfiniClone's Purelix series health products in the Southea
- INSIDERNew insider Huang Shanchun claimed ownership of 5,041,667 shares (SEC Form 3)3 - SHINECO, INC. (0001300734) (Issuer)
- SECShineco Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - SHINECO, INC. (0001300734) (Filer)
- PRShineco Announces Acquisition of Singapore Evolutionary Stem Cell CompanyExpanding the Frontiers of Regenerative Medicine BEIJING, April 23, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on April 22, 2025, its subsidiary, Shineco Life Sciences Group Hong Kong Limited ("Shineco Life Sciences"), entered into a Share Purchase Agreement (the "SPA") with Dr. Lim Kah Meng (the "Seller") to acquire 51% of the equity interest in InfiniClone Limited, a company incorporated under the laws of Hong Kong that has been wholly owned held by Dr. Lim ("InfiniClone"). InfiniClone is a biotechnology company focusing on the field of re